Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Current Liabilities (2017 - 2025)

Dianthus Therapeutics has reported Total Current Liabilities over the past 8 years, most recently at $23.9 million for Q3 2025.

  • Quarterly results put Total Current Liabilities at $23.9 million for Q3 2025, up 51.85% from a year ago — trailing twelve months through Sep 2025 was $23.9 million (up 51.85% YoY), and the annual figure for FY2024 was $18.5 million, up 91.59%.
  • Total Current Liabilities for Q3 2025 was $23.9 million at Dianthus Therapeutics, up from $20.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for DNTH hit a ceiling of $23.9 million in Q3 2025 and a floor of $4.0 million in Q2 2023.
  • Median Total Current Liabilities over the past 4 years was $12.9 million (2022), compared with a mean of $12.9 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 64.16% in 2023 and later surged 148.61% in 2024.
  • Dianthus Therapeutics' Total Current Liabilities stood at $8.2 million in 2022, then increased by 17.09% to $9.6 million in 2023, then skyrocketed by 91.59% to $18.5 million in 2024, then grew by 29.28% to $23.9 million in 2025.
  • The last three reported values for Total Current Liabilities were $23.9 million (Q3 2025), $20.1 million (Q2 2025), and $17.0 million (Q1 2025) per Business Quant data.